Search

Author(s): Aykut Demirkiran (corresponding author) [1]; Melek Karakurt Eryilmaz [1]; Mustafa Karaagac [1]; Murat Araz [1]; Mustafa Korkmaz [1]; Mehmet Zahid Koçak [1]; Mehmet Artac [1] INTRODUCTION Epithelial ovarian cancer [...], Objective: Bevacizumab (BEV) is a humanized monoclonal antibody of vascular endothelial growth factor receptors and, as a result of clinical trials, was approved for the treatment of recurrent ovarian cancer (ROC). The aim of this study was to assess the clinical utility of BEV in patients with ROC in real-world practice beyond clinical trials. Materials and Methods: In this single-center retrospective cohort study, we evaluated the medical data of all patients with ROC who were treated with BEV between October 2013 and March 2020. Results: A total of 76 females were evaluated. Forty-nine (64.5) patients were platinum sensitive and 27 (35.5) patients were platinum resistant. BEV was used in combination with chemotherapy agents in all patients, and the most preferred combinations were gemcitabine/carboplatin (GC) (78.9) and carboplatin/paclitaxel (14.5). In all patients, the BEV dose was 7.5 mg/kg every 3 weeks. The median progression-free survival (PFS) was 11.1 months (95 confidence interval [CI]: 9.6-12.6), and the median overall survival (OS) was 22.3 months (95 CI: 17.5-27.2). In multivariate analysis, serous histological type (P = 0.01), maintenance BEV administration (P = 0.001), and combination of GC-BEV (P < 0.001) were associated with better PFS, while serous histological type (P = 0.016) and good performance status (P = 0.006) were associated with prolonged OS. Conclusions: Low-dose (7.5 mg/kg) BEV was found to be effective in the second-line treatment of patients with ROC in our real-life study. In addition, the combination of BEV with GC was shown to be a viable option, especially in the treatment selection of platinum-resistant patients. Keywords: Bevacizumab, recurrent ovarian cancer, survival